Table 1.
Characteristics of AD and non-AD cohorts
| Characteristic | AD cohort N = 67,072 | Non-AD cohort N = 67,072 | P |
|---|---|---|---|
| Age at baseline, mean (95% CI) | 79.9 (79.8–79.9) | 79.9 (79.8–79.9) | matched |
| Age at first fracture during the follow-up | 84.1 (83.9–84.3) | 86.3 (86.1–86.5) | <0.001 |
| Sex | |||
| Men | 43158 (64.3) | 43158 (64.3) | matched |
| Women | 23914 (35.7) | 23914 (35.7) | |
| Highest occupational social class before follow-up | |||
| Managerial/professional | 14072 (21.0) | 14454 (21.5) | <0.001 |
| Office worker | 5608 (8.4) | 5629 (8.4) | |
| Farming/forestry | 12735 (19.0) | 13160 (19.6) | |
| Sales/industry/cleaning | 28669 (42.7) | 26180 (39.0) | |
| Unknown | 5470 (8.2) | 5186 (7.7) | |
| Did not respond | 518 (0.8) | 2463 (3.7) | |
| Hip replacement | 2219 (3.3) | 1001 (1.5) | <0.001 |
| Knee replacement | 105 (0.2) | 67 (0.1) | 0.004 |
| Cardiovascular disease | 34046 (50.8) | 32841 (49.0) | <0.001 |
| Stroke | 6356 (9.5) | 5232 (7.8) | <0.001 |
| Diabetes | 8969 (13.4) | 7527 (11.2) | <0.001 |
| Asthma/COPD | 5846 (8.7) | 6011 (9.0) | 0.11 |
| Cancer treatment | 792 (1.2) | 855 (1.3) | 0.12 |
| Any mental or behavioural disorder | 15365 (22.9) | 5917 (8.8) | <0.001 |
| Any CVD medication | 57603 (85.9) | 54704 (81.6) | <0.001 |
| Drugs for obstructive airway diseases | 15895 (23.7) | 15991 (23.8) | 0.54 |
| Hormone therapy use | 4429 (6.6) | 4213 (6.3) | 0.16 |
| Bisphosphonates | 8932 (13.3) | 7460 (11.1) | <0.001 |
| Proton pump inhibitors | 22281 (33.2) | 21760 (32.4) | 0.002 |
| Anti-Parkinson drugs | 2349 (3.5) | 1959 (2.9) | <0.001 |
| Antiepileptics drugs | 6729 (10.0) | 5697 (8.5) | <0.001 |
| Antipsychotics | 11127 (16.6) | 5364 (8.0) | <0.001 |
| Antidepressants | 23044 (34.4) | 13821 (20.6) | <0.001 |
| Benzodiazepines and related drugs | 29368 (43.8) | 25915 (38.6) | <0.001 |
| Opioids | 28907 (43.1) | 25742 (38.4) | <0.001 |
Data are given as n (%) unless otherwise indicated